candesartan has been researched along with Pancreatic Neoplasms in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gemcitabine was administered at a dose of 1,000 mg/m(2) over 30 min on days 1, 8, and 15 and oral candesartan at a dose of 16 mg in normotensive patients, and 8 mg initially in hypertensive patients, with dose escalation to 16 mg allowed, from days 1 to 28, repeated every 4 weeks." | 2.78 | A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. ( Arizumi, T; Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Miyabayashi, K; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Yagioka, H; Yamamoto, K; Yamamoto, N, 2013) |
| "Candesartan was given orally at an escalating dose (4, 8, 16, and 32 mg) q." | 2.77 | Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. ( Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mouri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Yagioka, H; Yamamoto, K; Yamamoto, N, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakai, Y | 2 |
| Isayama, H | 2 |
| Ijichi, H | 2 |
| Sasaki, T | 2 |
| Takahara, N | 1 |
| Ito, Y | 1 |
| Matsubara, S | 1 |
| Uchino, R | 1 |
| Yagioka, H | 2 |
| Arizumi, T | 1 |
| Hamada, T | 1 |
| Miyabayashi, K | 2 |
| Mizuno, S | 2 |
| Yamamoto, K | 2 |
| Kogure, H | 2 |
| Yamamoto, N | 2 |
| Hirano, K | 2 |
| Sasahira, N | 2 |
| Tateishi, K | 2 |
| Tada, M | 2 |
| Koike, K | 2 |
| Mouri, D | 1 |
| Kawakubo, K | 1 |
2 trials available for candesartan and Pancreatic Neoplasms
| Article | Year |
|---|---|
A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antimetabolites, Antineoplastic; A | 2013 |
Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1.
Topics: Adult; Aged; Antihypertensive Agents; Antimetabolites, Antineoplastic; Benzimidazoles; Biphenyl Comp | 2012 |